 |
38 Diseases |  |
6 Trials |
|
6 Trials |  |
127 News |  |
| «12 |
- |||| fosamprenavir / Generic mfg.
Trial completion: Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) - Jun 8, 2017
P3b/4, N=312, Completed, Sponsor: ViiV Healthcare
No longer recruiting --> Completed
- fosamprenavir / Generic mfg.
Phase classification, Combination therapy: Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) (clinicaltrials.gov) - May 30, 2017
P3b/4, N=20, Completed, Sponsor: ViiV Healthcare
No longer recruiting --> Completed Phase classification: P3 --> P3b/4
- | Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 7, 2017
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P3 --> P3b/4 Trial primary completion date: Jun 2018 --> Jun 2019
- Trial primary completion date: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Jan 4, 2017
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Dec 2016 --> Aug 2017
- |||| fosamprenavir / Generic mfg.
Trial completion, Phase classification: Fosamprenavir Expanded Access (clinicaltrials.gov) - Sep 12, 2016
P4, N=85, Completed, Sponsor: ViiV Healthcare
Trial primary completion date: Dec 2016 --> Aug 2017 No Longer Available --> Completed | Phase classification: P3 --> P4
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jun 9, 2016
P4, N=44, Active, not recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
No Longer Available --> Completed | Phase classification: P3 --> P4 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 29, 2016
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 N=1300 --> 1786
- Selzentry (maraviroc) / ViiV Healthcare
Phase classification, Combination therapy: An Interaction Study to Assess Drug Levels in Healthy Adult Subjects (clinicaltrials.gov) - Jan 30, 2016
P2, N=45, Completed, Sponsor: Garden State Infectious Disease Associates, PA
N=1300 --> 1786 Phase classification: P=N/A --> P2
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Jan 20, 2016
P4, N=76, Completed, Sponsor: Kirby Institute
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=28, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jul 31, 2015
P4, N=44, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 28, 2015
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Trial primary completion date: May 2016 --> Jun 2018
- | Enrollment open: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Feb 19, 2015
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: May 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- || New P3 trial: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Nov 28, 2014
P3, N=250, Not yet recruiting, Sponsor: University Hospital, Tours
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change, Trial primary completion date: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=28, Active, not recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Recruiting N=50 --> 28 | Trial primary completion date: Oct 2014 --> Jan 2015
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change, Trial primary completion date: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Jul 17, 2014
P4, N=75, Active, not recruiting, Sponsor: Kirby Institute
N=50 --> 28 | Trial primary completion date: Oct 2014 --> Jan 2015 N=150 --> 75 | Trial primary completion date: Oct 2014 --> Jan 2015
- fosamprenavir / Generic mfg.
Trial primary completion date: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
N=150 --> 75 | Trial primary completion date: Oct 2014 --> Jan 2015 Trial primary completion date: Oct 2013 --> Jun 2013
- fosamprenavir / Generic mfg.
Trial completion date: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
Trial primary completion date: Oct 2013 --> Jun 2013 Trial completion date: Nov 2013 --> Jun 2013
- | fosamprenavir / Generic mfg.
Enrollment change: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
Trial completion date: Nov 2013 --> Jun 2013 N=72 --> 42
- | fosamprenavir / Generic mfg.
Trial completion: FOSTER-C: HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir (clinicaltrials.gov) - May 28, 2014
P4, N=42, Completed, Sponsor: Fundacion SEIMC-GESIDA
N=72 --> 42 Recruiting --> Completed
- || fosamprenavir / Generic mfg.
Trial completion date: Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) - May 7, 2014
P2, N=75, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Completed Trial completion date: Jul 2011 --> Jun 2021
- ||| fosamprenavir / Generic mfg.
Enrollment closed: Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) - May 7, 2014
P2, N=75, Active, not recruiting, Sponsor: ViiV Healthcare
Trial completion date: Jul 2011 --> Jun 2021 Completed --> Active, not recruiting
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 5, 2014
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Active, not recruiting Trial primary completion date: May 2014 --> May 2016
- |||| Invirase (saquinavir) / Roche, NN1213 / Novo Nordisk
Trial completion: Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127) (clinicaltrials.gov) - Feb 22, 2014
P2, N=61, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Trial primary completion date: May 2014 --> May 2016 No longer recruiting --> Completed
- ||||||| lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks (clinicaltrials.gov) - Feb 22, 2014
P3, N=866, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years (clinicaltrials.gov) - Feb 22, 2014
P2, N=69, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed Recruiting --> Completed
- | tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion, Combination therapy: Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=56, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (clinicaltrials.gov) - Feb 22, 2014
P2, N=53, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment closed: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Dec 16, 2013
P4, N=150, Active, not recruiting, Sponsor: Kirby Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment closed: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Dec 16, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Kirby Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| fosamprenavir / Generic mfg.
Trial completion: Fosamprenavir in Pts With Hepatic Impairment (clinicaltrials.gov) - May 1, 2013
P=N/A, N=167, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Mycobutin (rifabutin) / Pfizer, Lupin
Enrollment change: Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications (clinicaltrials.gov) - Apr 16, 2013
P=N/A, N=63, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=46 --> 63
- Mycobutin (rifabutin) / Pfizer, Lupin
Trial completion: Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications (clinicaltrials.gov) - Apr 16, 2013
P=N/A, N=63, Completed, Sponsor: University of California, San Francisco
N=46 --> 63 Active, not recruiting --> Completed
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 11, 2013
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=800 --> 1300
- |||| ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection (clinicaltrials.gov) - Dec 5, 2012
P2, N=110, Completed, Sponsor: ViiV Healthcare
N=800 --> 1300 Active, not recruiting --> Completed
- |||| fosamprenavir / Generic mfg.
Trial completion: Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) - Dec 5, 2012
P2, N=75, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Jul 9, 2012
P4, N=150, Active, not recruiting, Sponsor: Kirby Institute
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=12 --> 8
- Isentress (raltegravir) / Merck (MSD)
Trial completion: PLUS: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Francisco
N=12 --> 8 Recruiting --> Completed
- tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Enrollment change: Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (clinicaltrials.gov) - Apr 2, 2012
P2, N=53, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=108 --> 53
- | omega-3 ethylester concentrate / Generic mfg., fosamprenavir / Generic mfg.
Enrollment change: BuLLET: Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects (clinicaltrials.gov) - Mar 25, 2012
P4, N=36, Completed, Sponsor: Felizarta, Franco, M.D.
N=108 --> 53 N=50 --> 36
- | omega-3 ethylester concentrate / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: BuLLET: Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects (clinicaltrials.gov) - Mar 25, 2012
P4, N=36, Completed, Sponsor: Felizarta, Franco, M.D.
N=50 --> 36 Recruiting --> Completed
- fosamprenavir / Generic mfg.
Trial completion: PENTA Fosamprenavir Study (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=1, Completed, Sponsor: ViiV Healthcare
Recruiting --> Completed Active, not recruiting --> Completed
- sorafenib / Generic mfg.
New P2 trial, Metastases: A FEASIBILITY STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR (HCC) CARCINOMA AND HIV INFECTION TREATED WITH HAART REGIMENS Studio di fattibilita' che valuta l'efficacia e la tolleranza del Sorafenib (NEXAVAR) associato alla terapia antiretrovirale altamente efficace (HAART) nei pazienti con infezione da HIV ed epatocarcinoma avanzato. (EUDRACT) - Dec 15, 2011
P2, N=38, Ongoing, Sponsor: CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
- ||| fosamprenavir / Generic mfg.
Enrollment change: Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) - Nov 17, 2011
P2, N=75, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed N=48 --> 75
- ||||||| efavirenz / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT (clinicaltrials.gov) - Oct 13, 2011
P3, N=101, Completed, Sponsor: Georgetown University
N=48 --> 75 Active, not recruiting --> Completed